 |
Journal articles
Sustained virological and biochemical responses to lamivudine and adefovir dipivoxil combination in a chronic hepatitis B infection despite mutations conferring resistance to both drugs.
Abstract : ABSTRACT: BACKGROUND: Sequential monotherapies of nucleotide analogs used in chronic hepatitis B treatment can lead to the selection of a resistance mutation to each antiviral drug. CASE PRESENTATION: A patient with chronic hepatitis B was successively treated with lamivudine monotherapy, lamivudine-adefovir dual therapy, adefovir monotherapy and again with an adefovir-lamivudine dual therapy. Lamivudine-associated mutations (rtL180M and rtM204V/I) followed by adefovir-associated mutations (rtN236T and rtA181V) emerged during the two monotherapy regimens. Despite the presence of rtM204V/I, rtA181V, and rtN236T mutations at the beginning of the second dual therapy, sustained biochemical and virological responses have been observed thus far after 23 months. CONCLUSION: This case illustrates that rtM204V/I, rtA181V, and rtN236T resistance mutations can coexist in a patient but do not preclude the recycling of lamivudine and adefovir in combination therapy, when no other therapeutic choices are available.
https://www.hal.inserm.fr/inserm-00324951
Contributor : Alain Duperray <>
Submitted on : Thursday, September 25, 2008 - 5:06:50 PM
Last modification on : Thursday, August 27, 2020 - 11:36:03 AM
Contributor : Alain Duperray <>
Submitted on : Thursday, September 25, 2008 - 5:06:50 PM
Last modification on : Thursday, August 27, 2020 - 11:36:03 AM
Links full text
